Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Fourth Quarter and Full Year of 2014

Call Scheduled for Thursday, March 12, 2015 at 4:30 P.M.

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced today that it will host a conference call on Thursday, March 12, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the fourth quarter and full year of 2014.

Interested parties may access the call live by dialing [phone] (US) or [phone] (international) and using conference ID 7292518.

A live audio webcast of the presentation will be available via the “Investor Relations” page of the Ocata website, www.ocata.com. A replay of the webcast will be archived on Ocata’s website for 90 days.

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

About Dry Age-related Macular Degeneration

Age-related macular degeneration is the leading cause of vision loss in people over the age of 50. Every year in the USA there are 1.8 million patients newly diagnosed with dry AMD which occurs when light-sensitive photoreceptor cells in the macula, located in the center of the retina, slowly break down, causing vision loss as a result. Photoreceptor breakdown is a consequence of loss or damage to the retinal pigment epithelium (“RPE”) layer. As the disease progresses, patients may have difficulty reading and recognizing faces. There is currently no proven medical therapy for dry AMD and the projected number of people worldwide with age-related macular degeneration in 2020 is 196 million, increasing to 288 million in 2040 underscoring the urgent need for new treatments.

About Stargardt’s Disease

Stargardt’s macular degeneration is a form of juvenile macular degeneration that affects vision in children and young adults between the ages of six and 20, with a prevalence of approximately one in 10,000 people in the United States. It is an orphan disease and loss of vision is an inevitable aspect of SMD, with more than half of the patients experiencing vision loss in the range of 20/200-20/400. Like dry AMD, it occurs as a result of damage to the RPE layer and there are no treatments currently approved to prevent or slow the vision loss associated with SMD.

Investors:Westwicke PartnersJohn Woolford, [e-mail]:Russo PartnersDavid Schull, [e-mail]